Daniel F B Wright1, Stephen B Duffull1, Tony R Merriman2, Nicola Dalbeth3, Murray L Barclay4,5, Lisa K Stamp4. 1. School of Pharmacy, University of Otago, Dunedin. 2. Department of Biochemistry, University of Otago, Dunedin. 3. Department of Medicine, University of Auckland, Auckland. 4. Department of Medicine, University of Otago, Christchurch. 5. Department of Clinical Pharmacology, Christchurch Hospital, Christchurch, New Zealand.
Abstract
AIMS: The primary aim of this research was to predict the allopurinol maintenance doses required to achieve the target plasma urate of ≤0.36 mmol l(-1) . METHODS: A population analysis was conducted in nonmem using oxypurinol and urate plasma concentrations from 133 gout patients. Maintenance dose predictions to achieve the recommended plasma urate target were generated. RESULTS: The urate response was best described by a direct effects model. Renal function, diuretic use and body size were found to be significant covariates. Dose requirements increased approximately 2-fold over a 3-fold range of total body weight and were 1.25-2 fold higher in those taking diuretics. Renal function had only a modest impact on dose requirements. CONCLUSIONS: Contrary to current guidelines, the model predicted that allopurinol dose requirements were determined primarily by differences in body size and diuretic use. A revised guide to the likely allopurinol doses to achieve the target plasma urate concentration is proposed.
AIMS: The primary aim of this research was to predict the allopurinol maintenance doses required to achieve the target plasma urate of ≤0.36 mmol l(-1) . METHODS: A population analysis was conducted in nonmem using oxypurinol and urate plasma concentrations from 133 goutpatients. Maintenance dose predictions to achieve the recommended plasma urate target were generated. RESULTS: The urate response was best described by a direct effects model. Renal function, diuretic use and body size were found to be significant covariates. Dose requirements increased approximately 2-fold over a 3-fold range of total body weight and were 1.25-2 fold higher in those taking diuretics. Renal function had only a modest impact on dose requirements. CONCLUSIONS: Contrary to current guidelines, the model predicted that allopurinol dose requirements were determined primarily by differences in body size and diuretic use. A revised guide to the likely allopurinol doses to achieve the target plasma urate concentration is proposed.
Authors: Daniel F B Wright; Stephen B Duffull; Tony R Merriman; Nicola Dalbeth; Murray L Barclay; Lisa K Stamp Journal: Br J Clin Pharmacol Date: 2015-12-29 Impact factor: 4.335
Authors: Michael A Becker; H Ralph Schumacher; Robert L Wortmann; Patricia A MacDonald; Denise Eustace; William A Palo; Janet Streit; Nancy Joseph-Ridge Journal: N Engl J Med Date: 2005-12-08 Impact factor: 91.245
Authors: C C Wen; S W Yee; X Liang; T J Hoffmann; M N Kvale; Y Banda; E Jorgenson; C Schaefer; N Risch; K M Giacomini Journal: Clin Pharmacol Ther Date: 2015-04-06 Impact factor: 6.875
Authors: Sophie L Stocker; Kenneth M Williams; Andrew J McLachlan; Garry G Graham; Richard O Day Journal: Clin Pharmacokinet Date: 2008 Impact factor: 6.447
Authors: Klaus Stark; Wibke Reinhard; Martina Grassl; Jeanette Erdmann; Heribert Schunkert; Thomas Illig; Christian Hengstenberg Journal: PLoS One Date: 2009-11-05 Impact factor: 3.240
Authors: Daniel F B Wright; Stephen B Duffull; Tony R Merriman; Nicola Dalbeth; Murray L Barclay; Lisa K Stamp Journal: Br J Clin Pharmacol Date: 2015-12-29 Impact factor: 4.335
Authors: Diluk R W Kannangara; Garry G Graham; Daniel F B Wright; Sophie L Stocker; Ian Portek; Kevin D Pile; Murray L Barclay; Kenneth M Williams; Lisa K Stamp; Richard O Day Journal: Br J Clin Pharmacol Date: 2017-05-28 Impact factor: 4.335
Authors: Mark D Russell; Andrew I Rutherford; Benjamin Ellis; Sam Norton; Abdel Douiri; Martin C Gulliford; Andrew P Cope; James B Galloway Journal: Lancet Reg Health Eur Date: 2022-05-25
Authors: Daniel Fb Wright; Matthew P Doogue; Murray L Barclay; Peter T Chapman; Nicholas B Cross; John H Irvine; Lisa K Stamp Journal: Eur J Clin Pharmacol Date: 2016-09-28 Impact factor: 2.953
Authors: Daniel F B Wright; Nicola Dalbeth; Amanda J Phipps-Green; Tony R Merriman; Murray L Barclay; Jill Drake; Paul Tan; Anne Horne; Lisa K Stamp Journal: Br J Clin Pharmacol Date: 2018-02-20 Impact factor: 4.335